Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Sharesting ....easy tiger ! You won't sleep tonight if you get over excited this time of night ;-) haha
Just on the annual report and trial. SNG001 had the best of the best working on the hospital trials. I think they will try and achieve emergency approval based of a combination of Hospital and COPD data + historic Asthma data. Just my opinion.
At home proactive use is a huge market as well. The mind boggles at how big this could get !!
Yea i suspect you're right. A combination of them making sure patients met the entry requirements (72 hour since Infection), coupled with the delay in adequate testing times may have resulted in the delay in recruitment. If that is the case then it was a very disciplined and professional approach under immense pressure to 'just fill up the numbers.
I get the impression they want (and are hopeful) of skipping stage 3 trials and getting to market. In what other scenario would they draw home trials to a conclusion early unless Covid slowed up? Positive hospital result? They have given themselves as much time as possible to manipulate the data. Looking back now I wonder if the delay on recruitment was due to the change they filed for the hospital study maybe they didn’t take many patients until they got the tests done quicker and established this at an early stage before many were dosed. Could point to it being more tailored to what they needed which can only be positive.
Indeed Crookie, but as they say trial could be finished before they attain 120 patients in that respect. Also as I understand it they can widen the net in search of Covid sufferers if they deem fit.
I'm not so sure Crookie. I was of the opinion about 2 weeks ago that the the hospital may not show the levels of improvement to get this over the line on its own however the report posted here last week on interferon 1B through IV showed an improvement of c.20% in hospital patients (14 day discharge and 28 day mortality rates). Coupled with the way SNG meticulously took their time in hospital trial enrollment, I'm feeling a lot more confident. If the hospital data is good then the home trial may be a bit of a slow burner whilst the drug gets approved.
"Data from the hospital trial will read out during the summer, and, if positive, the Company will work closely with regulators to determine an expeditious route to securing approval for SNG001"
They may not need to wait for the 3rd result (home trial) to crack on with approvals.
I agree Ghia. The manner in which the company continue to conduct themselves in a market that is dominated by those who shout loudest just oozes confidence. Although they quite rightly highlight the risks, the other data that has been posted here (thank you all!) about the benefit of interferons is a huge de-risking factor for me.
Pressure is on to get the home trial completed though, there is clearly some concern that numbers May will be tough to get Quickly. Looks like it needs to be done quickly with fixed costs per month. Let’s hope for positive data as clearly a tie up with a big company is possible.
ChrisToffer - Indeed it did make great reading. I believe our patience will be rewarded, and things may move very quickly off the back of a good trial result.
That annual report is fantastic! Love the company outlook
"Data from the hospital trial will read out during the summer, and, if positive, the Company will work closely with regulators to determine an expeditious route to securing approval for SNG001, a treatment we believe could play an important role in addressing the current COVID-19 crisis and similar viruses in the future. In parallel the Company is now working with manufacturers to scale up for potential demand for SNG001. The outlook for the business is positive and we look forward to updating the market on further progress in due course."
It does also highlight the risks involved (that the drug does not work) as well as showing the commercial aim,
"Our customers are the large pharmaceutical
and biotech companies who have the resources
and infrastructure to take our products to
market. It is therefore critical that we interact
with these companies at an early stage to make
sure we are developing a product which they
may wish to license."
I honestly think it is that approach that is behind the uninding of the COPD trial data. Very reassuring report.